{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:16:55Z","timestamp":1792120615200,"version":"4.4.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"66","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30\u00a0CA076292-22S4"],"award-info":[{"award-number":["P30\u00a0CA076292-22S4"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There has been limited study regarding patient-provider communication about medical cannabis for cancer symptom management. To address this gap, this study assesses the determinants and prevalence of patient-provider communication about the use of medical cannabis for cancer symptoms at a National Cancer Institute\u2013designated Comprehensive Cancer Center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Individuals who completed cancer treatment from July 2017 to December 2019 were invited to participate in a survey regarding medical cannabis. An electronic survey was administered in English and Spanish from August to November 2021 and completed by 1592 individuals (response rate = 17.6%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>About one-third (33.5%) of participants reported discussing medical cannabis for cancer symptom management with a health-care provider. Controlling for other factors, individuals with malnutrition and\/or cachexia had higher odds (odds ratio [OR] = 2.30, 95% confidence interval [CI] = 1.50 to 3.53) of reporting patient-provider discussions compared with individuals without malnutrition and\/or cachexia. Similarly, individuals with nausea had higher odds (OR = 1.94, 95% CI = 1.44 to 2.61) of reporting patient-provider discussions compared with individuals without nausea. A smaller percentage (15.6%) of participants reported receiving a recommendation for medical cannabis for cancer symptom management. Among individuals who reported using cannabis, a little over one-third (36.1%) reported not receiving instructions from anyone on how to use cannabis or determine how much to take.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Overall, our study suggests that patient-provider communication about medical cannabis for cancer symptom management is limited. As interest and use of medical cannabis continues to grow among cancer patients, there is a need to ensure patients have access to high quality patient-provider communication.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncimonographs\/lgad026","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:13:58Z","timestamp":1723068838000},"page":"298-304","source":"Crossref","is-referenced-by-count":7,"title":["Patient-provider communication about the use of medical cannabis for cancer symptoms: a cross-sectional study"],"prefix":"10.1093","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7885-0879","authenticated-orcid":false,"given":"Kea","family":"Turner","sequence":"first","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center , Tampa, FL, USA"},{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center , Tampa, FL, USA"},{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Y","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"},{"name":"Department of Cancer Epidemiology, Moffitt Cancer Center , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahana","family":"Rajasekhara","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"},{"name":"Department of Supportive Care Medicine, Moffitt Cancer Center , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yessica C","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology, Moffitt Cancer Center , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Alishahi","family":"Tabriz","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center , Tampa, FL, USA"},{"name":"Department of Gastrointestinal Oncology, Moffitt Cancer Center , Tampa, FL, USA"},{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center , Tampa, FL, USA"},{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S L","family":"Jim","sequence":"additional","affiliation":[{"name":"Department of Health Outcomes and Behavior, Moffitt Cancer Center , Tampa, FL, USA"},{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Egan","sequence":"additional","affiliation":[{"name":"Department of Oncological Sciences, University of South Florida , Tampa, FL, USA"},{"name":"Department of Cancer Epidemiology, Moffitt Cancer Center , Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"2024080708113141700_lgad026-B1","author":"NCSL"},{"issue":"13","key":"2024080708113141700_lgad026-B2","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.32059","article-title":"The role of cancer in marijuana and prescription opioid use in the United States: a population-based analysis from 2005 to 2014","volume":"125","author":"Tringale","year":"2019","journal-title":"Cancer"},{"issue":"21","key":"2024080708113141700_lgad026-B3","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/cncr.33794","article-title":"Cannabis use among cancer survivors in the United States: analysis of a nationally representative sample","volume":"127","author":"Do","year":"2021","journal-title":"Cancer"},{"issue":"18","key":"2024080708113141700_lgad026-B4","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1002\/cncr.33646","article-title":"Prevalence of cannabis use among individuals with a history of cancer in the United States","volume":"127","author":"Cousins","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"2024080708113141700_lgad026-B5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.33202","article-title":"Cancer patients\u2019 experiences with medicinal cannabis-related care","volume":"127","author":"Braun","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"2024080708113141700_lgad026-B6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/can.2018.0029","article-title":"Oncology clinicians and the Minnesota medical cannabis program: a survey on medical cannabis practice patterns, barriers to enrollment, and educational needs","volume":"3","author":"Zylla","year":"2018","journal-title":"Cannabis Cannabinoid Res"},{"issue":"11","key":"2024080708113141700_lgad026-B7","doi-asserted-by":"crossref","first-page":"e1762","DOI":"10.1200\/OP.21.00714","article-title":"Oncology fellows\u2019 clinical discussions, perceived knowledge, and formal training regarding medical cannabis use: a national survey study","volume":"18","author":"Patell","year":"2022","journal-title":"J Clin Oncol Oncol Pract"},{"key":"2024080708113141700_lgad026-B8","author":"CRS"},{"issue":"2","key":"2024080708113141700_lgad026-B9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/1527154421989609","article-title":"Medicinal cannabis: policy, patients, and providers","volume":"22","author":"Ryan","year":"2021","journal-title":"Policy Polit Nurs Pract"},{"issue":"2","key":"2024080708113141700_lgad026-B10","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.3747\/co.27.5615","article-title":"Health care provider preferences for, and barriers to, cannabis use in cancer care","volume":"27","author":"McLennan","year":"2020","journal-title":"Curr Oncol"},{"issue":"19","key":"2024080708113141700_lgad026-B11","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.2017.76.1221","article-title":"Medical oncologists\u2019 beliefs, practices, and knowledge regarding marijuana used therapeutically: a nationally representative survey study","volume":"36","author":"Braun","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024080708113141700_lgad026-B12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/jpm.2022.0433","article-title":"Comparison of health care providers attitudes and beliefs regarding medical marijuana and cannabidiol in the management of pain and other symptoms in cancer patients","volume":"26","author":"Tanco","year":"2023","journal-title":"J Palliat Med"},{"key":"2024080708113141700_lgad026-B13","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"2024080708113141700_lgad026-B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2024080708113141700_lgad026-B15","author":"NCI"},{"issue":"10","key":"2024080708113141700_lgad026-B16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1089\/jpm.2018.0528","article-title":"Medical cannabis use in glioma patients treated at a comprehensive cancer center in Florida","volume":"22","author":"Reblin","year":"2019","journal-title":"J Palliat Med"},{"issue":"10","key":"2024080708113141700_lgad026-B17","first-page":"34","article-title":"Measuring community vulnerability to natural and anthropogenic hazards: the centers for disease control and prevention\u2019s social vulnerability index","volume":"80","author":"Flanagan","year":"2018","journal-title":"J Environ Health"},{"issue":"5","key":"2024080708113141700_lgad026-B18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10552-023-01683-1","article-title":"The social vulnerability index as a risk stratification tool for health disparity research in cancer patients: a scoping review","volume":"34","author":"Tran","year":"2023","journal-title":"Cancer Causes Control"},{"issue":"3","key":"2024080708113141700_lgad026-B19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5055\/jom.2009.0016","article-title":"Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions","volume":"5","author":"Aggarwal","year":"2009","journal-title":"J Opioid Manag"},{"issue":"3","key":"2024080708113141700_lgad026-B20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00280-017-3387-5","article-title":"A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics","volume":"80","author":"Badowski","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024080708113141700_lgad026-B21","doi-asserted-by":"crossref","first-page":"107667","DOI":"10.1016\/j.addbeh.2023.107667","article-title":"Prevalence of cannabis use disorder among individuals using medical cannabis at admission to inpatient treatment for substance use disorders","volume":"142","author":"N S Gendy","year":"2023","journal-title":"Addict Behav"},{"issue":"1","key":"2024080708113141700_lgad026-B22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"11","key":"2024080708113141700_lgad026-B23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"issue":"12","key":"2024080708113141700_lgad026-B24","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"key":"2024080708113141700_lgad026-B25","doi-asserted-by":"crossref","first-page":"102675","DOI":"10.1016\/j.ctim.2021.102675","article-title":"Medical cannabis education among healthcare trainees: A scoping review","volume":"58","author":"Zolotov","year":"2021","journal-title":"Complement Ther Med"},{"key":"2024080708113141700_lgad026-B26","doi-asserted-by":"crossref","first-page":"102328","DOI":"10.1016\/j.ctim.2020.102328","article-title":"Cannabis education needs assessment among Canadian physicians-in-training","volume":"49","author":"St Pierre","year":"2020","journal-title":"Complement Ther Med"},{"key":"2024080708113141700_lgad026-B27","doi-asserted-by":"crossref","first-page":"21501327211042790","DOI":"10.1177\/21501327211042790","article-title":"Practice Patterns and Training Needs Among Physicians Certifying Patients for Medical Marijuana in Florida","volume":"12","author":"Sajdeya","year":"2021","journal-title":"J Prim Care Community Health"},{"issue":"4","key":"2024080708113141700_lgad026-B28","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s11764-022-01297-7","article-title":"Medical cannabis-related stigma: Cancer survivors\u2019 perspectives","volume":"17","author":"Nayak","year":"2023","journal-title":"J Cancer Surviv"},{"key":"2024080708113141700_lgad026-B29","doi-asserted-by":"crossref","first-page":"102204","DOI":"10.1016\/j.ctim.2019.102204","article-title":"Exploring cancer survivors\u2019 attitudes, perceptions, and concerns about using medical cannabis for symptom and side effect management: a qualitative focus group study","volume":"47","author":"Victorson","year":"2019","journal-title":"Complement Ther Med"},{"issue":"2","key":"2024080708113141700_lgad026-B30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pec.2008.01.002","article-title":"Randomized study of different anti-stigma media","volume":"71","author":"Finkelstein","year":"2008","journal-title":"Patient Educ Couns"},{"issue":"5","key":"2024080708113141700_lgad026-B31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s00520-015-3014-0","article-title":"Association between patient-provider communication and lung cancer stigma","volume":"24","author":"Shen","year":"2016","journal-title":"Support Care Cancer"},{"issue":"6","key":"2024080708113141700_lgad026-B32","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1177\/02692163221083437","article-title":"Efficacy of medicinal cannabis for appetite-related symptoms in people with cancer: a systematic review","volume":"36","author":"Razmovski-Naumovski","year":"2022","journal-title":"Palliat Med"},{"issue":"21","key":"2024080708113141700_lgad026-B33","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.2005.05.1847","article-title":"Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the","volume":"24","author":"Strasser","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"2024080708113141700_lgad026-B34","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1007\/s00520-018-4154-9","article-title":"The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial","volume":"26","author":"Turcott","year":"2018","journal-title":"Support Care Cancer"},{"issue":"5","key":"2024080708113141700_lgad026-B35","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s00520-019-05280-4","article-title":"Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis","volume":"28","author":"Chow","year":"2020","journal-title":"Support Care Cancer"},{"key":"2024080708113141700_lgad026-B36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejim.2021.05.002","article-title":"\u201cIs medical cannabis safe for my patients?\u201d A practical review of cannabis safety considerations","volume":"89","author":"MacCallum","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2024080708113141700_lgad026-B37","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2147\/IJGM.S275049","article-title":"Safety considerations in cannabinoid-based medicine","volume":"13","author":"Gottschling","year":"2020","journal-title":"Int J Gen Med"},{"issue":"12","key":"2024080708113141700_lgad026-B38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"2024080708113141700_lgad026-B39","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8070989","article-title":"Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use","volume":"8","author":"Brown","year":"2019","journal-title":"J Clin Med"},{"issue":"11","key":"2024080708113141700_lgad026-B40","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2024080708113141700_lgad026-B41","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1634\/theoncologist.2018-0383","article-title":"Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies","volume":"24","author":"Taha","year":"2019","journal-title":"Oncologist"},{"issue":"9","key":"2024080708113141700_lgad026-B42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092447","article-title":"Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome","volume":"12","author":"Bar-Sela","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2024080708113141700_lgad026-B43","doi-asserted-by":"crossref","first-page":"e1777","DOI":"10.1200\/OP.21.00748","article-title":"Description and disposition of patients with cancer accessing a novel, pharmacist-led cannabis consultation service","volume":"18","author":"Marchese","year":"2022","journal-title":"J Clin Oncol Oncol Pract"},{"issue":"3","key":"2024080708113141700_lgad026-B44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3747\/co.25.3983","article-title":"Rates of cannabis use in patients with cancer","volume":"25","author":"Martell","year":"2018","journal-title":"Curr Oncol"},{"issue":"10","key":"2024080708113141700_lgad026-B45","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1089\/jpm.2018.0529","article-title":"Patterns of medical cannabis use among cancer patients from a medical cannabis dispensary in New York State","volume":"22","author":"Kim","year":"2019","journal-title":"J Palliat Med"},{"issue":"1","key":"2024080708113141700_lgad026-B46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cncr.33906","article-title":"A Coala-T-Cannabis Survey Study of breast cancer patients\u2019 use of cannabis before, during, and after treatment","volume":"128","author":"Weiss","year":"2022","journal-title":"Cancer"},{"issue":"22","key":"2024080708113141700_lgad026-B47","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"key":"2024080708113141700_lgad026-B48","author":"Statista"},{"issue":"1","key":"2024080708113141700_lgad026-B49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/s12889-022-13076-1","article-title":"Availability of medical cannabis services by racial, social, and geographic characteristics of neighborhoods in New York: a cross-sectional study","volume":"22","author":"Cunningham","year":"2022","journal-title":"BMC Public Health"},{"issue":"2","key":"2024080708113141700_lgad026-B50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review","volume":"112","author":"Ford","year":"2008","journal-title":"Cancer"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2024\/66\/298\/58749555\/lgad026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2024\/66\/298\/58749555\/lgad026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T22:14:16Z","timestamp":1723068856000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2024\/66\/298\/7728477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":50,"journal-issue":{"issue":"66","published-online":{"date-parts":[[2024,8,7]]},"published-print":{"date-parts":[[2024,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgad026","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,8]]}}}